Patient: Page 25
-
PharmaVoice Team/PharmaVoice
Healthcare Reform and Comparative Effectiveness
We all know that R&D focus, pharmaceutical promotion, pricing, and reimbursement are all, or will be, critically affected by the biggest U.S. healthcare reform to occur in 40 years. The impact is going to be disruptive, but overall, experts says it will be a positive gain for the pharmaceutic...
By PharmaVoice Team • Nov. 10, 2010 -
PharmaVoice Team/PharmaVoice
The Sales Force of the Future
Of all the factors that will influence how sales reps perform their jobs tomorrow, experts outline training, specialty roles, and social media as the top three that will most influence the size, strategies, and success of sales forces in the future. Training is Crucial. As new skill sets become ...
By PharmaVoice Team • Nov. 10, 2010 -
Explore the Trendline➔
Stock via Getty Images
TrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Comparative Effectiveness: Real-World Evidence of Outcomes
Comparative effectiveness research is going to have a huge impact on every stakeholder in healthcare delivery. It requires a much broader view of the healthcare system so that information will exist about a patient’s outcome as he or she moves from diagnosis to treatment in the healthcare system....
By PharmaVoice Team • Aug. 27, 2010 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharmaceutical POOL Lonnel COATS Eisai Names CEO for U.S. Subsidiary Eisai Inc., a U.S. subsidiary of Japan’s Eisai Co., has promoted Lonnel Coats to president and CEO, from president and chief operating officer. In addition, Mr. Coats has been appointed senior VP of Eisai Co.’s pharmaceuticals b...
By PharmaVoice Team • Aug. 26, 2010 -
PharmaVoice Team/PharmaVoice
Software as a Service: Gaining Traction
Many research firms have predicted that the worldwide economic recession is responsible for the global increase in the software-as-a-service (SaaS) market revenue. According to a recent Gartner report, SaaS is forecast to have a 17.7% compound annual growth rate through 2013 for the aggregate ent...
By PharmaVoice Team • March 23, 2010 -
PharmaVoice Team/PharmaVoice
Advertising In the Digital Age
The difficult economic environment of the past 18 months has forced many pharma companies to reexamine their shrinking advertising budgets and make best use of the resources that remain. Sandra Peterson, president of the Bayer Medical Care unit of Bayer HealthCare, notes that Bayer HealthCare rec...
By PharmaVoice Team • March 12, 2010 -
PharmaVoice Team/PharmaVoice
Opportunities in Oncology Development
Advances in cancer research, knowledge, treatment options, and awareness have increased tremendously in the past 25 years. Rates of new diagnoses and deaths from all cancers have declined significantly for men and women overall and for most racial and ethnic populations in the United States, acco...
By PharmaVoice Team • Jan. 28, 2010 -
PharmaVoice Team/PharmaVoice
The Patient Pipeline
CLINICAL TRIAL RECRUITMENT AND ENROLLMENT EFFORTS ARE OFTEN NOT GIVEN HIGH PRIORITY, causing costly delays in the develop ment of new drugs. Unfortunately, there are no quick fixes, but companies are beginning to institute wellthought out and designed processes to bring the right patients to the ...
By PharmaVoice Team • Jan. 18, 2010 -
PharmaVoice Team/PharmaVoice
Industry Heal Thyself
The right MEDICINE TREWHITT. More than a year ago, key members of PhRMA’s executive board identified that there was a need to revisit the guidelines and make some improvements to eliminate the periodic complaints and allegations about the practices of sales representatives and their relationships...
By PharmaVoice Team • Jan. 11, 2010 -
PharmaVoice Team/PharmaVoice
The Salesforce of the Future
Our experts agree: the salesforce of the future will be more specialized, more technically advanced, and more clinically savvy; oh, and there will be fewer feet on the street, finally. If the past year is any indication, the salesforce of the future is going to experience an extreme makeover. For...
By PharmaVoice Team • Nov. 10, 2009 -
PharmaVoice Team/PharmaVoice
R&D Business Models
The Changing R&D Business Model Companies throughout the industry are experimenting with new models designed to tackle the pipeline productivity challenge. harmaceutical research and development is facing many pressures, from decreased productivity to the impact of the economy to changing tec...
By PharmaVoice Team • Nov. 10, 2009 -
PharmaVoice Team/PharmaVoice
Emerging Markets Poised for Growth
Emerging markets are growing in size and in importance for drug developers. Countries outside the traditional markets of the United States, Europe, and Japan are revamping their regulatory and legal systems and reforming their healthcare systems, and they are expected to contribute more to the gl...
By PharmaVoice Team • Nov. 10, 2009 -
PharmaVoice Team/PharmaVoice
CRM: Connecting the Dots...
CUSTOMER RELATIONSHIP MANAGEMENT BY TAREN GROM CRM requires a multilevel, enterprisewide view of customers — thereby demanding a strong customer data management business practice . A 5% increase in customer retention can lead to a 25% to 85% profit increase,depending on the industry. — HarvardBus...
By PharmaVoice Team • Nov. 4, 2009 -
PharmaVoice Team/PharmaVoice
E-learning: A Virtual Classroom
Pharmaceutical companies are jumping on board the etrain as a way to better manage their internal learning initiatives The THE CLICK MAY NEVER REPLACE THE NO. 2 PENCIL, but elearning is becoming the teacher’s pet in terms of reach, content flexibility, access, and alleviating outofoffice downtime...
By PharmaVoice Team • Nov. 2, 2009 -
PharmaVoice Team/PharmaVoice
Sales Reps — What's Up Doc?
The relationship between the pharmaceutical sales representative and the physician has undergone a dramatic shift in recent years. In the past, the sales representative provided value to the physician, had an established and meaningful rela tionship, engaged in an interactive dialog, and acted as...
By PharmaVoice Team • Nov. 2, 2009 -
PharmaVoice Team/PharmaVoice
Creating Opportunity From Diversity
bring messages about their products to diverse groups in a way that is culturally sensitive, that will garner longterm goodwill of the communities, and that address the most press ing health concerns facing various racial and ethnic groups. Developing diverse marketing promotions and programs whe...
By PharmaVoice Team • Nov. 2, 2009 -
PharmaVoice Team/PharmaVoice
Planting the Seeds of a Blockbuster
Until fairly recently, top tier pharmaceutical companies obtained license rights to a product developed by a biotechnology company, thereby infusing much needed capital for furtherance of clinical research. In return, the pharmaceutical company obtained outright or major ity rights to marketing a...
By PharmaVoice Team • Oct. 23, 2009 -
PharmaVoice Team/PharmaVoice
Coming Into Focus
The pharmaceutical powerhouses have either been U.S. or European companies, and all have extensive operations in the U.S. Of the top 10 pharmaceutical companies, six are U.S.based companies, the remaining four have their headquarters either in the United Kingdom or continental Europe, according t...
By PharmaVoice Team • Oct. 23, 2009 -
PharmaVoice Team/PharmaVoice
Beyond the Genome — Proteomics
Drug discovery in the postgenomic era will lead researchers to focus on the proteins and biological mechanisms that cause disease as a way to develop new types of treatments that are safer and more effective BY DENISE MYSHKO When the initial map of the human genome was first published in February...
By PharmaVoice Team • Oct. 23, 2009 -
PharmaVoice Team/PharmaVoice
The Knowledge Revolution
In 20 to 25 years, pharmaceutical research and development will be multidimensional. Scientists will use artificial intelligence and robotics and interact through a global networked Web. Modeling and simulations that work at different levels, including digital models of “virtual patients," will b...
By PharmaVoice Team • Aug. 24, 2009 -
PharmaVoice Team/PharmaVoice
The Creative Challenge
BY TAREN GROM CHARLENE PROUNIS Our clients are afraid to take risks. The original concept often gets very watered down and loses its flair.There are so many people who are involved in the decision making process, by the time an ad gets approved it’s defaulted to the lowest common denominator. Cha...
By PharmaVoice Team • Aug. 12, 2009 -
PharmaVoice Team/PharmaVoice
Vanlev: Coming Soon
In a second round for a drug that once was predicted to become a high flier, BristolMyers Squibb is one FDA approval away from launching the next best medication for the treatment of hypertension, a condition that affects about 50 million Americans. Nearly two years ago, BristolMyers Squibb was s...
By PharmaVoice Team • Aug. 12, 2009 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Consumer shifts demand changes in healthcare marketing In its latest report on market insights, Cheskin, a strategic market research and consulting company, defines three consumer trends that are driving the evolution of the healthcare and lifesci ences industry: consumer enlightenment and empowe...
By PharmaVoice Team • March 10, 2009 -
PharmaVoice Team/PharmaVoice
GLOBAL Development
BY DENISE MYSHKO Drug developers are looking to emerging markets and increasing their outsourcing efforts as ways to access expertise and reach. Pharmaceutical companies will continue to globalize their preclinical and clinical development activities to increase speed-to-market and expand their p...
By PharmaVoice Team • Feb. 26, 2009 -
PharmaVoice Team/PharmaVoice
Buying Big GLOBAL
How M&A Impacts the Pharma Market As patent expirations and dwindling pipelines, along with an embattled economy, put a dent on pharma profits, acquisitions again become a necessity for large pharma companies seeking to maintain a healthy bottom line. With Pfizer’s purchase of Wyeth, among ot...
By PharmaVoice Team • Feb. 26, 2009
Previous
